

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Autoimmune disease</b>				
Psoriasis	IL-1 receptor-like 2 (IL1RL2; IL-36R)	<p>Mouse studies suggest antagonizing IL-36R could help treat psoriasis. In a mouse model of psoriasis, knocking out <i>Il-36r</i> protected mice from psoriasis symptoms and decreased recruitment of inflammatory macrophages and neutrophils compared with what was seen in wild-type controls. Knocking out the <i>Il-36 receptor antagonist</i> (<i>IL36RN</i>; <i>IL-1F5</i>) led to a more severe disease phenotype. Next steps could include developing IL-36R antagonists.</p> <p><b>SciBX 5(43); doi:10.1038/scibx.2012.1131</b>  <b>Published online Nov. 1, 2012</b></p>	Patent and licensing status unavailable	<p>Tortola, L. <i>et al. J. Clin. Invest.</i>; published online Oct. 15, 2012;            doi:10.1172/JCI63451  <b>Contact:</b> Manfred Kopf, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland            e-mail:  <a href="mailto:manfred.kopf@ethz.ch">manfred.kopf@ethz.ch</a></p>